2023 Speaker Faculty | Kisaco Research

2023 Speaker Faculty

Microbiome Connect
November 2023
BOSTON, USA
  • Author:

    Gabriel Leventhal

    CSO
    PharmaBiome

    Gabriel Leventhal

    CSO
    PharmaBiome
  • Author:

    Pedro Correa de Sampaio

    CEO
    Neobe Therapeutics

    Pedro Correa de Sampaio

    CEO
    Neobe Therapeutics
  • Author:

    Romain Daillere

    Head of Preclinical Research, Co-Founder
    Everimmune

    Romain Daillere

    Head of Preclinical Research, Co-Founder
    Everimmune
  • Author:

    Jean-Luc Marsat

    CEO
    Everimmune

    Jean-Luc Marsat

    CEO
    Everimmune
  • Author:

    Aaron Cowley, Ph.D., MBA

    Chief Scientific Officer
    ReciBioPharm

    Aaron Cowley, Ph.D., MBA

    Chief Scientific Officer
    ReciBioPharm
  • Author:

    Benjamin Hadida

    Chief Executive Officer
    Exeliom Biosciences

    Benjamin Hadida

    Chief Executive Officer
    Exeliom Biosciences
  • Author:

    Osnat Tirosh

    Head of Microbiome Research and Innovation
    Biomica

    Osnat Tirosh

    Head of Microbiome Research and Innovation
    Biomica
  • Author:

    Juan Basterra

    CEO
    Mikrobiomik

    Juan Basterra

    CEO
    Mikrobiomik
  • Author:

    Shahram Lavasani

    CEO
    ImmuneBiotech

    Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech´s first product GutMagnific® has been designed to address the underlying causes of IBS and it is currently investigated, in collaboration with Karolinska Institute, for treatment of chronic fatigue syndrome (ME/CFS) a neuroimmune condition and a possible long-term effect of Covid-19. GutMagnific® has successfully been launched in October 2019. 

    Shahram Lavasani

    CEO
    ImmuneBiotech

    Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech´s first product GutMagnific® has been designed to address the underlying causes of IBS and it is currently investigated, in collaboration with Karolinska Institute, for treatment of chronic fatigue syndrome (ME/CFS) a neuroimmune condition and a possible long-term effect of Covid-19. GutMagnific® has successfully been launched in October 2019. 

  • Author:

    Eric Van der Helm

    VP Scientific Affairs, Bioinformatics & Automation
    SNIPR Bio

    Eric Van der Helm

    VP Scientific Affairs, Bioinformatics & Automation
    SNIPR Bio
  • Author:

    Anna Chwalibog

    CEO, Co-founder
    Integral Solutions

    Anna Chwalibog

    CEO, Co-founder
    Integral Solutions
  • Author:

    Evelina Vågesjö, PhD MBA

    CEO
    Ilya Pharma

    Co-founder of and developed the concept during PhD 2011-2016, is now CEO and heading the drug and business development in Ilya Pharma. Also BSc in Management Accounting and finished an MBA 2018. Raised >4.3 M€ in grant funding to the project, lead the first private share issue in 2017 and designed stock option programs for key employees.  

    Evelina Vågesjö, PhD MBA

    CEO
    Ilya Pharma

    Co-founder of and developed the concept during PhD 2011-2016, is now CEO and heading the drug and business development in Ilya Pharma. Also BSc in Management Accounting and finished an MBA 2018. Raised >4.3 M€ in grant funding to the project, lead the first private share issue in 2017 and designed stock option programs for key employees.  

  • Author:

    Nathalie Corvaia

    CSO
    MaaT Pharma

    Nathalie Corvaia

    CSO
    MaaT Pharma
  • Author:

    Chrysi Sergaki

    Microbiome Group Leader
    MHRA

    Chrysi Sergaki

    Microbiome Group Leader
    MHRA
  • Author:

    Steve Emery

    CSO
    Chain Biotech

    Steve Emery

    CSO
    Chain Biotech
  • Author:

    Sarah Lebeer

    Professor
    University of Antwerp

    Sarah Lebeer

    Professor
    University of Antwerp
  • Author:

    Ruben Vazquez Uribe

    Co-principal Investigator
    Novo Nordisk Foundation Center for Biosustainability

    Ruben Vazquez Uribe

    Co-principal Investigator
    Novo Nordisk Foundation Center for Biosustainability
  • Author:

    Adam Baker

    Director of Sciences
    Chr. Hansen

    Adam Baker

    Director of Sciences
    Chr. Hansen
  • Author:

    Harriet Schellekens

    Lecturer
    University College Cork

    Harriet Schellekens

    Lecturer
    University College Cork
  • Author:

    Pilar Manrique Ronquillo

    Research Scientist
    Microviable Tx

    Pilar Manrique Ronquillo

    Research Scientist
    Microviable Tx
  • Author:

    Rosanne Hertzberger

    PI
    Vrije Universiteit Amsterdam

    Rosanne Hertzberger

    PI
    Vrije Universiteit Amsterdam
  • Author:

    Lothar Steidler

    CTO
    ActoBio Tx

    Lothar Steidler

    CTO
    ActoBio Tx
  • Author:

    Jonathan Swann

    Professor
    University of Southampton

    Jonathan Swann

    Professor
    University of Southampton
  • Author:

    Selin Bolca

    Head of Development
    MRM Health

    Selin Bolca

    Head of Development
    MRM Health
  • Author:

    Johan E.T. van Hylckama Vlieg

    Chief Scientific Officer
    Freya Biosciences

    Johan E.T. van Hylckama Vlieg

    Chief Scientific Officer
    Freya Biosciences
  • Author:

    Christophe Roca

    Pilot Plant Manager
    Sacco Systems

    Christophe Roca

    Pilot Plant Manager
    Sacco Systems
  • Author:

    Stella Ackrell

    VP, Pharmaceutical Development
    Destiny Pharma

    Stella Ackrell

    VP, Pharmaceutical Development
    Destiny Pharma